Dyserythropoietic anemia, congenital type 3

Congenital Dyserythropoietic Anemia Type III
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Anemia, jaundice, splenomegaly
Complications	Gallstones, iron overload
Onset	Birth or early childhood
Duration	Lifelong
Types	N/A
Causes	Genetic mutation
Risks	N/A
Diagnosis	Blood tests, bone marrow biopsy
Differential diagnosis	N/A
Prevention	N/A
Treatment	Supportive care, blood transfusions
Medication	N/A
Prognosis	N/A
Frequency	N/A
Deaths	N/A

Congenital Dyserythropoietic Anemia Type III (CDA III) is a rare genetic disorder characterized by ineffective erythropoiesis and distinct morphological abnormalities in erythroblasts. It is one of the subtypes of congenital dyserythropoietic anemia (CDA), a group of hereditary anemias.

Etiology

CDA III is caused by mutations in the KIF23 gene, which is located on chromosome 15. This gene encodes a protein involved in the final stages of cell division, particularly in the separation of daughter cells. The mutation leads to abnormal cell division in erythroid precursors, resulting in the characteristic features of the disease.

Pathophysiology

The hallmark of CDA III is the presence of giant multinucleated erythroblasts in the bone marrow. These cells exhibit ineffective erythropoiesis, leading to anemia. The ineffective erythropoiesis is due to the inability of the erythroblasts to undergo normal mitosis and cytokinesis, resulting in the formation of these abnormal cells.

Clinical Features

Patients with CDA III typically present with:

• Anemia: This is usually mild to moderate and may be associated with fatigue and pallor.
• Jaundice: Due to increased breakdown of red blood cells.
• Splenomegaly: Enlargement of the spleen is common due to increased destruction of abnormal erythrocytes.

Complications can include:

• Gallstones: Due to increased bilirubin production.
• Iron overload: From repeated blood transfusions or increased intestinal iron absorption.

Diagnosis

Diagnosis of CDA III involves:

• Complete blood count (CBC) showing anemia.
• Peripheral blood smear revealing abnormal erythrocytes.
• Bone marrow biopsy demonstrating giant multinucleated erythroblasts.
• Genetic testing to identify mutations in the KIF23 gene.

Treatment

There is no cure for CDA III, and treatment is primarily supportive. Management strategies include:

• Regular blood transfusions to manage severe anemia.
• Iron chelation therapy to prevent iron overload.
• Splenectomy in cases of severe splenomegaly or hypersplenism.

Prognosis

The prognosis for individuals with CDA III is generally good, with most patients maintaining a reasonable quality of life with appropriate management. However, they require lifelong monitoring for complications such as iron overload.

Also see

• Congenital dyserythropoietic anemia
• Anemia
• Erythropoiesis
• Genetic disorders